近日，博纳西亚(杭州)医药科技股份有限公司(简称：博纳西亚)向港交所主板递交上市申请，兴证国 际、工银国际为其联席保荐人。 招股书显示，这家总部位于杭州的临床合同研究组织(CRO)致力于通过数字化赋能创新药临床研究，深 耕肿瘤及自身免疫性疾病两大领域，于2024年已取得约6729.1万元盈利。不过，与此同时，公司现金 流、应收账款状况面临考验，且公司市场份额并不占优，或将成为市场投资者担忧的因素。 在巨头林立的CRO行业，博纳西亚讲述的"小而美"故事，能否收获投资者青睐? 2025年业绩回暖 毛利率稳步上行 财务数据显示，博纳西亚的业绩在经历2024年的短暂回调后，于2025年重回增长轨道。公司于2023年 度、2024年度分别录得收入约为3.71亿元、3.40亿元(单位为人民币，下同)，年内利润为6241.2万元、 6729.1万元，其中2024年收入下滑主要受行业整体环境影响。 智通财经APP了解到，随着公司业务恢复增长，2025年截至9月30日止九个月，公司收入约为2.45亿， 相比去年同期的2.37亿元同比增长3.38%;期内利润为4522万元，相比去年同期的4456.2万元同比增长 1.48%。 | ...

消息面上，泰格医药近日公告，此预计2025年实现营业收入66.6亿-76.8亿元，同比增长1%至16%；归属 于上市公司股东的净利润为8.3亿-12.3亿元，同比增长105%至204%；归属于上市公司股东的扣除非经常 性损益后的净利润约3.3亿-4.9亿元，同比下降61%至43%。当期业绩增长主要由金融资产的投资收益和 公允价值变动贡献，而非临床CRO核心业务驱动。 里昂发布研报称，泰格医药的订单情况有所改善，但市场更关注公司的订单转化收入效率及投资变现能 力。由于短期利好因素已反映在股价，相信其风险与回报已趋于平衡。该行下调泰格医药2027财年盈测 7%，以反映长期投资收益的不确定因素增加。 泰格医药（300347）(03347)尾盘跌超5%，截至发稿，跌4.85%，报51港元，成交额1.3亿港元。 ...

消息面上，泰格医药近日公告，此预计2025年实现营业收入66.6亿-76.8亿元，同比增长1%至16%；归属 于上市公司股东的净利润为8.3亿-12.3亿元，同比增长105%至204%；归属于上市公司股东的扣除非经常 性损益后的净利润约3.3亿-4.9亿元，同比下降61%至43%。当期业绩增长主要由金融资产的投资收益和 公允价值变动贡献，而非临床CRO核心业务驱动。 里昂发布研报称，泰格医药的订单情况有所改善，但市场更关注公司的订单转化收入效率及投资变现能 力。由于短期利好因素已反映在股价，相信其风险与回报已趋于平衡。该行下调泰格医药2027财年盈测 7%，以反映长期投资收益的不确定因素增加。 智通财经APP获悉，泰格医药(03347)尾盘跌超5%，截至发稿，跌4.85%，报51港元，成交额1.3亿港 元。 ...

智通财经APP获悉，据港交所2月11日披露，博纳西亚（杭州）医药科技股份有限公司(简称：博纳西亚)向港交所主板递交上市申请，兴证国际、工银国际为 其联席保荐人。 招股书披露，博纳西亚是一家总部位于中国杭州的临床合同研究组织（「CRO」）机构，致力于通过数字化赋能创新药临床研究。公司的核心业务是为国 内外制药及生物技术公司提供临床试验技术服务，旨在加速化学药物和生物制品的研发及商业化进程。 公司将数字化系统整合到临床研究过程中，助力制药及生物技术公司快速、高效地将创新药及创新疗法带给患者。这一数字化赋能通过战略性运用数据驱动 与自动化工作流，赋能临床研究全生命周期的关键阶段。此外，公司秉持以效率为导向的运营模式与精细化的管理体系，加快研发进程、降低研发投入并提 升项目运营效率。 公司的临床CRO服务主要专注于临床试验技术服务，服务范围涵盖整个临床开发过程，包括新药临床试验申请（「IND」）、I-IV期临床研究、新药上市申 请（「NDA」）注册申报以及FSP服务及其他服务。 公司简介 此外，公司通过灵活的人力资源提供FSP服务，部署全职或基于项目的人员来支持整个临床试验过程的特定功能模块。公司庞大的人才库使公司能 ...

Core Viewpoint - The stock price of Tigermed (03347) has shown a significant rebound after a period of decline, primarily driven by the company's earnings forecast for 2025, which has garnered market attention and investor interest [1][2]. Group 1: Stock Performance - Tigermed's stock price has rebounded from a low of 36.08 HKD on November 21 last year to a peak of 54.85 HKD on January 15, marking a maximum increase of 52.02% [1]. - Following a technical decline, the stock price fell below 50 HKD but rebounded sharply on January 29 and 30, indicating a stabilization in its price trend [1]. - The stock price jumped to 56.25 HKD the day after the earnings forecast was released, reflecting strong buying interest from investors [3]. Group 2: Earnings Forecast - Tigermed's earnings forecast for 2025 predicts revenue between 6.66 billion and 7.68 billion CNY, representing a year-on-year growth of 1% to 16% [2]. - The net profit attributable to shareholders is expected to be between 830 million and 1.23 billion CNY, showing a significant increase of 105% to 204% [2]. - However, the growth in net profit is largely attributed to non-recurring gains, which are expected to be between 500 million and 740 million CNY, indicating that the core business did not drive this growth [2]. Group 3: Market Sentiment and Institutional Response - Following the earnings forecast, Goldman Sachs adjusted its profit forecasts for Tigermed, lowering estimates for 2025 while slightly increasing those for 2026 and 2027, and raised the target price for its H-shares to 66.4 HKD [3]. - UBS also set a target price of 57.1 HKD for Tigermed, emphasizing the importance of monitoring new order prices and management guidance for 2026 [3]. - The trading activity in the secondary market indicates a strong buying sentiment, with a significant increase in trading volume following the earnings announcement [3]. Group 4: Industry Trends - The domestic healthcare financing market has shown signs of recovery, with a 22% year-on-year increase in financing amounts in the first three quarters of 2025, indicating a shift towards more substantial clinical investments [10]. - The approval rates for innovative drug applications have improved, with a 96.5% approval rate for INDs, suggesting a more favorable regulatory environment for clinical projects [10][11]. - The demand for clinical CRO services is expected to rise as companies increase their clinical trial investments, benefiting leading firms in the industry [11]. Group 5: Business Model and Strategy - Tigermed's strategy of "investing to support research" has proven advantageous, with new order volumes expected to grow significantly compared to the previous year [11]. - This model is not unique to Tigermed, as many CRO companies are adopting similar strategies to expand their market presence [12]. - However, this business model carries inherent risks, as fluctuations in industry conditions can impact both the core CRO business and the investment returns, leading to increased stock volatility [12].

Group 1 - The core viewpoint of the article is that Yinos (688710.SH) is planning to acquire a controlling stake in Yilinsi to enhance its integrated service solutions in the biopharmaceutical non-clinical research sector [1][2] - The acquisition aims to improve the company's upstream and downstream industry chain layout, establishing a comprehensive service system that covers drug research from early concept validation to industrial incubation [1][2] - Yilinsi, established in February 2004, specializes in clinical trial services, focusing on phases I to IV of new drug clinical trials, pharmacokinetics research, and various clinical trial management services [1] Group 2 - This transaction is a strategic move in response to national policies encouraging mergers and acquisitions among listed companies to enhance their core business and industry chain [2] - The acquisition will extend the company's business chain, enhance service segments, and strengthen collaboration among different business units, thereby improving the company's competitive edge and industry foundation [2] - Yilinsi is a high-tech enterprise and has a mature system and professional capabilities in the clinical research service field, which will significantly enhance the company's comprehensive service capabilities and long-term competitiveness [2]

Group 1 - The core viewpoint of the article is that Yinos (688710.SH) is planning to acquire a controlling stake in Yilinsi to enhance its integrated service solutions in the biopharmaceutical non-clinical research sector [1][2] - The acquisition aims to improve the company's upstream and downstream industry chain layout, establishing a comprehensive service system that covers drug research from early concept validation to industrial incubation [1][2] - Yilinsi, established in February 2004, specializes in clinical trial services, focusing on phases I to IV of new drug clinical trials, pharmacokinetics research, and various clinical trial management services [1][2] Group 2 - This transaction is a strategic move in response to national policies encouraging mergers and acquisitions among listed companies to enhance their core business and industry chain [2] - The acquisition will extend the company's business chain, enhance service segments, and strengthen collaboration among different business units, thereby improving the overall quality of development [2] - Yilinsi is a high-tech enterprise and has a mature system and professional capabilities in the clinical research service field, which will significantly enhance the company's comprehensive service capabilities and competitive edge in the industry [2]

Core Insights - The CRO industry in China is experiencing significant growth, with the market size expected to expand from 90 billion yuan in 2021 to 126 billion yuan by 2024, reflecting a compound annual growth rate (CAGR) of 28%, which is substantially higher than the global average of 10% [13][26] - The industry is characterized by a clear competitive landscape, with WuXi AppTec as the dominant player, achieving revenue exceeding 20 billion yuan, while other key players include Kanglong Chemical, Tigermed, and Kelun Pharmaceutical [17][20] Industry Overview - Contract Research Organizations (CROs) are specialized entities that undertake drug development responsibilities on behalf of pharmaceutical companies, helping to reduce costs and risks while ensuring compliance [1] - The CRO industry is divided into preclinical and clinical segments, with preclinical CROs focusing on drug discovery and safety evaluations, while clinical CROs handle clinical trials and data management [1] Industry Development History - The CRO industry in China began in 1996 with the establishment of the first joint venture, and has evolved from a lack of formal organizations to a competitive landscape dominated by local leaders [9] - The industry has undergone significant changes, including the implementation of Good Clinical Practice (GCP) in 2003 and the introduction of the Marketing Authorization Holder (MAH) system, which has facilitated the growth of CRO services [11] Market Demand and Growth - The number of New Drug Applications (NDA) in China has been increasing, from 210 in 2021 to an expected 320 by 2024, driving demand for CRO services [14] - The global CRO market is projected to grow from 71 billion USD in 2021 to 90 billion USD by 2024, driven by increased healthcare demands due to aging populations and the COVID-19 pandemic [13] Competitive Landscape - The competitive structure of the Chinese CRO industry is categorized into three tiers, with WuXi AppTec leading the first tier, followed by Kanglong Chemical and Tigermed in the second tier, and smaller firms in the third tier [17] - Most companies are diversifying their services to include both CRO and CDMO (Contract Development and Manufacturing Organization) capabilities, enhancing operational efficiency [20] Regional Market Dynamics - The Yangtze River Delta region dominates the CRO market in China, accounting for approximately 43% of the market share, followed by the Beijing-Tianjin-Hebei region at 23% and the Pearl River Delta at 19% [23] Future Outlook - The Chinese CRO market is expected to continue its growth trajectory, potentially exceeding 144 billion yuan by 2028, supported by favorable policies and increasing demand for innovative therapies [26] - Despite challenges such as rising compliance costs and market saturation, the overall outlook remains positive, with expectations of sustained double-digit growth over the next five years [26]

Investment Rating - The investment rating for the company is "Buy" for both A and H shares, maintained from previous assessments [7]. Core Insights - The company has demonstrated steady performance with a revenue of 10.086 billion RMB and a non-IFRS adjusted net profit of 1.227 billion RMB for the first three quarters of 2025, reflecting year-on-year growth of 14.4% and 10.8% respectively [1]. - The company has raised its revenue growth guidance for 2025 from 10-15% to 12-16%, indicating strong confidence in its growth prospects [1]. - The acquisition of Wuxi Bai'ao is expected to enhance the company's integrated service capabilities and international reach, aligning with its strategic focus on a comprehensive, integrated, and multi-therapy approach [3][4]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported a gross margin of 34.2%, an increase of 0.4 percentage points year-on-year, supported by scale effects and improved capacity utilization in its CMC business [1]. - The net cash flow from operating activities reached 2.436 billion RMB, marking a year-on-year increase of 37.6% [1]. - The company’s new order intake grew by over 13% year-on-year, with a notable acceleration in the third quarter [2]. Business Segments - The laboratory services segment, as the flagship business, generated 6.004 billion RMB in revenue, up 15.0% year-on-year, with new orders increasing by over 12% [2]. - The CMC segment reported revenue of 2.293 billion RMB, reflecting a year-on-year growth of 16.0%, with new orders increasing by approximately 20% [2]. - The clinical CRO segment achieved revenue of 1.440 billion RMB, up 10.3% year-on-year, while the large molecules and CGT segment saw revenue of 336 million RMB, an 8.1% increase [2]. Acquisition Details - The company plans to acquire 82.54% of Wuxi Bai'ao for approximately 1.346 billion RMB, which is positioned as a leading CRO in structural biology [3]. - The acquisition is expected to create strong synergies, leveraging Bai'ao's advanced capabilities in structural biology and protein preparation, enhancing the company's service offerings [4]. Profit Forecast and Valuation - The projected net profits for the company from 2025 to 2027 are 1.729 billion RMB, 2.105 billion RMB, and 2.529 billion RMB respectively, with slight upward adjustments from previous estimates [5]. - The company is assigned a PE ratio of 37x for A shares and 26x for H shares in 2026, with target prices set at 43.81 RMB and 33.69 HKD respectively [5].

Investment Rating - The report gives a "Buy" rating for the company, 康龙化成, for the first time [1][9]. Core Views - 康龙化成 is positioned as a leading global drug research and development enterprise with a comprehensive, integrated, international, and multi-therapy approach. The company is expected to experience significant growth across its various service segments, including laboratory services, small molecule CDMO, clinical CRO, and large molecule and cell gene therapy services [6][8][9]. Financial Summary - Total revenue projections for 康龙化成 are as follows: - 2024: 12,276 million CNY - 2025: 13,816 million CNY - 2026: 15,688 million CNY - 2027: 17,879 million CNY - The expected growth rates are 6.4% for 2024, 12.5% for 2025, 13.5% for 2026, and 14.0% for 2027 [2]. - Net profit attributable to shareholders is projected to be: - 2024: 1,793 million CNY - 2025: 1,689 million CNY - 2026: 1,959 million CNY - 2027: 2,257 million CNY - The expected growth rates for net profit are 12.0% for 2024, -5.8% for 2025, 15.9% for 2026, and 15.2% for 2027 [2]. Business Segments Laboratory Services - Laboratory services are the most competitive segment for 康龙化成, contributing significantly to revenue and profit. In 2024, this segment is expected to generate revenue of 70.47 billion CNY, accounting for 57.4% of total revenue [23]. - The segment has shown a compound annual growth rate (CAGR) of 24.25% in revenue from 2015 to 2024 [23][26]. CMC (Small Molecule CDMO) Services - The CMC segment is entering a commercialization phase, with revenue expected to reach 29.89 billion CNY in 2024, representing 24% of total revenue [45]. - The company has established four FDA-approved production bases in China, the UK, and the US, enhancing its capacity for global clients [49][53]. Clinical CRO Services - The clinical CRO segment is expected to generate revenue of 18.26 billion CNY in 2024, accounting for 14.87% of total revenue [63]. - The company has built a comprehensive clinical CRO service platform across China, the US, and the UK, which is anticipated to enhance efficiency and profitability [66]. Large Molecule and Cell Gene Therapy Services - The company is rapidly advancing in large molecule and cell gene therapy services, with expectations of approximately 10% revenue growth over the next three years [6][20]. Valuation and Price Target - The target price for 康龙化成 is set at 47.73 CNY based on a 40x PE ratio for 2026 adjusted net profit. The corresponding target price for the Hong Kong market is 39.34 HKD based on a 30x PE ratio [2][9].